Whiteoak Capital Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹500

Whiteoak Capital Pharma & Healthcare Growth Direct Plan

NAV
₹14.6480
+0.69%
(20 Oct)
AUM
443 Cr
TER
0.66%
Risk
Very High Risk
Insights
Asset Under Management (AUM) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+10.4%
+5.0%
+1.3%
+0.7%
-1.6%
3Y
NA
+31.7%
+32.1%
+31.8%
+30.6%
5Y
NA
+29.2%
+34.5%
+33.1%
+35.5%
ALL
+25.1%
+18.4%
+12.2%
+17.1%
+25.1%
VOL
14.9%
16.2%
20.1%
19.7%
22.1%
TER
0.7%
0.5%
0.8%
0.9%
0.6%
AUM
₹443 Cr
₹7,766 Cr
₹5,521 Cr
₹1,418 Cr
₹5,533 Cr
INFO
1.68
1.13
0.60
0.87
1.13
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Whiteoak Capital Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Sep
Top holdings
Clearing Corporation Of India Ltd
7.1%
J.B. Chemicals & Pharmaceuticals Ltd
6.9%
Sun Pharmaceuticals Industries Ltd
6.8%
Fortis Healthcare Ltd
6.7%
Cipla Ltd
4.6%
Laurus Labs Ltd
4.3%
Krishna Institute of Medical Sciences Ltd
4.1%
Neuland Laboratories Ltd
3.2%
Max Healthcare Institute Ltd Ordinary Shares
3.2%
Lupin Ltd
3.1%
Top industry exposure
Healthcare
84.5%
Basic Materials
4.1%
Financial Services
0.5%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹500
Additional lumpsum
₹500
Portfolio turnover
252%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
Fund manager(s)
Piyush Baranwal
Ramesh Mantri
Trupti Agrawal
Dheeresh Pathak
Ashish Agrawal

FAQs